Welcome to our dedicated page for Profusa SEC filings (Ticker: NVACW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Profusa, Inc. filings document the digital health company’s securities registration activity, material events, and public-company status. Its S-1 and S-1/A registration statements describe offering-related disclosures, security structure, capital structure, risk factors, and the company’s status as an emerging growth company and smaller reporting company.
Profusa’s 8-K reports cover Nasdaq listing compliance matters, material agreements, shareholder voting matters, and other capital-structure or security-structure disclosures. These filings provide the formal record for corporate events affecting the company and its warrant security.
Profusa, Inc. (PFSA) had a Form 4 filed by major shareholder HRT Financial LP, a ten percent owner. On August 14, 2026, HRT Financial LP reported selling 3,163 shares of Profusa common stock at $0.902 per share, leaving it with 71,035 shares held directly.
HRT FINANCIAL LP, a more than ten percent owner of Profusa, Inc., reported mixed trading in Profusa common stock. On August 13, 2026, it sold 42,411 shares at $0.888 per share. On August 12, 2026, it purchased 5,585 shares at $0.964 per share. Overall, these transactions represent a net sale of 36,826 shares.
Profusa, Inc. approved and implemented a one-for-four (1:4) reverse stock split of its common stock. The reverse split becomes effective at 12:01 a.m. Eastern Time on August 17, 2026, after which the common stock will trade on The Nasdaq Capital Market on a post-split basis under ticker PFSA with a new CUSIP 74319X405.
At the effective time, every four issued and outstanding shares of common stock will be combined into one share, with the par value remaining $0.0001 per share. The number of shares outstanding will be reduced from 2,422,906 to approximately 605,726, while authorized common shares remain at 601 million. Proportionate adjustments will be made to outstanding equity awards and warrants, including exercise prices and shares reserved under the equity incentive plan.
No fractional shares will be issued; instead, each holder entitled to a fraction will receive cash based on the closing price on the effectiveness date. Profusa also provided illustrative pre- and post-split net loss per share and weighted average shares data for 2024–2026 reporting periods.
HRT FINANCIAL LP, a ten percent owner of Profusa, Inc., reported mixed trading in the company’s common stock. On 10 August 2026 it purchased 4,016 shares at $0.944 per share, and on 11 August 2026 it sold 2,280 shares at $0.97 per share.
Profusa, Inc. reported insider trading activity by HRT FINANCIAL LP, a ten percent owner of PFSA. Over August 5–7, 2026, the holder executed a mix of open-market trades in common stock, including 926 shares purchased at $0.943 and sales totaling 1,307 shares at prices around $0.94–0.95, resulting in a net reduction of 381 shares. The Rule 10b5-1 plan checkbox was not marked for these transactions.
HRT Financial LP, listed as a ten percent owner of Profusa, Inc., reported open-market purchases of a total of 15,924 shares of common stock on August 3 and 4, 2026, at per-share prices of $0.958 and $0.954. The filing does not mark the Rule 10b5-1 trading plan checkbox.
A group of investment entities and individuals led by Ascent Partners Fund LLC reports beneficial ownership of Profusa, Inc. common stock. The group has shared voting and dispositive power over 58,749 shares of common stock, representing 9.99% of the class as of June 30, 2026, subject to a contractual ownership cap.
The stake arises from convertible promissory notes effective on several dates and a Securities Purchase Agreement (the ELOC Agreement) that allows Profusa, at its option and subject to a 9.99% beneficial ownership limitation (the Blocker), to require purchases of common stock. Ownership percentages are calculated using 186,411 shares outstanding as of May 12, 2026, adjusted for a 1-for-25 reverse stock split effective July 7, 2026, plus shares issuable upon partial note conversions and ELOC purchases, all constrained by the Blocker.
Profusa, Inc. large shareholder HRT Financial LP, identified as a ten percent owner, reported two non-derivative purchases of Profusa common stock. It bought 8,811 shares at $1.05 per share on July 31, 2026 and 1,063 shares at $1.01 on July 30, 2026, for total reported purchases of 9,874 shares.
Profusa, Inc. entered into an Option Agreement granting it a call option to acquire all equity of G3 Vision Labs Inc., which owns Med Screen Laboratories, Dominion Diagnostics and Acutis Diagnostics, so these businesses would become Profusa subsidiaries if the option is exercised. G3’s 2025 net revenues are estimated at approximately $111 million based on unaudited management information.
The option can be exercised for 90 days after G3 delivers specified financial information, subject to conditions including at least $30 million in aggregate financings, refinancing or consent of G3 debt, required stockholder approvals and continued Nasdaq listing. As consideration, Profusa issued 201,120 common shares and 52,903.566 Series A Non-Voting Convertible Preferred shares, each convertible into 1,000 common shares upon stockholder approval, with an additional 53,918.113 preferred shares issuable if the option is exercised. Profusa believes that, as a result of this issuance, it has at least $2.5 million in stockholders’ equity, meeting the equity standard for continued listing on The Nasdaq Capital Market, and established dividend parity, protective voting rights and an Automatic Conversion feature for the new preferred series, subject to a Beneficial Ownership Limitation.